Article Figures & Data
Tables
Study Mean Baseline NIHSS Recanalization (TIMI 2 or 3) Good Outcome at 90 Days (mRS 0–2) Mortality at 90 Days Symptomatic ICH Intra-arterial therapy PROACT9 17 58% NA 27% 15% PROACT II6 17 66% 40% 25% 10% IMS-I8 18 56% 43% 16% 6% IMS-II5 19 60% 46% 16% 10% MERCI7 22 46% 28% 44% 8% Multi MERCI4 19 68% 36% 34% 10% Penumbra pivotal study 18 82% 25% 33% 11% Nonarterial therapy PROACT9 19 14% NA 43% 7% PROACT II2 control 17 18% 25% 27% 2% NINDS placebo*5 18 NA 28% 24% 1% NINDS IV rtPA*5 18 NA 39% 21% 7% Note:—NIHSS indicates National Institutes of Health Stroke Scale; TIMI, Thrombolysis in Myocardial Infarction trial; ICH, intracranial hemorrhage; mRS, modified Rankin Scale; PROACT, Prolyse in Acute Cerebral Thromboembolism trial; IMS, Interventional Management of Stroke trials; MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials; NINDS, National Institute of Neurological Disorders and Stroke; NA, not available.
* NINDS is subgroup of patients with an NIHSS of 10 or more.
Report Cases per Year per Hospital* Intra-arterial treatment, multicenter trials PROACT, 19989 1 (0–10) PROACT II, 19996 1 (0–17) EMS, 199966 5 (2–10) IMS-I, 20048 7 (0–27) MERCI, 20057 3 (0–9) IMS-II, 20075 2 (NA) Multi MERCI, 20084 5 (0–20) Intra-arterial treatment, single center Barnwell et al, 199419 7 Suarez et al, 199918 15 Jahan et al, 199967 5 Ernst et al, 200020 17 Hill et al, 200221 4 Ramee et al, 200468 3 Choi et al, 200622 9 Devlin et al, 200723 30 Kim et al, 200717 13 Wolfe et al, 200816 15 Intravenous treatment, multicenter trials NINDS, 199569 20 ATLANTIS, 199970 1 STARS, 200071 4 Intravenous treatment, single center Chiu et al, 199872 30 Zweifler et al, 199873 9 Grotta et al, 200174 61 Kahn et al, 200575 26 Wolfe et al, 200816 45 Arenillas et al76 46 Note:—PROACT indicates Prolyse in Acute Cerebral Thromboembolism trial; EMS, Emergency Management of Stroke trial; IMS, Interventional Management of Stroke trials; MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials; NINDS, National Institute of Neurological Disorders and Stroke; ATLANTIS, Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke trial; STARS, Standard Treatment with Alteplase to Reverse Stroke study.
* Numbers in parentheses are ranges.